In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 30, No. 15_suppl ( 2012-05-20), p. 4044-4044
Abstract:
4044 Background: Patients (pts) with advanced pancreatic cancer (APC) often suffer from symptomatic thromboembolic events (sVTE). The CONKO-004 trial showed that the low molecular weight heparin (LMWH) enoxaparin reduces sVTE (p 〈 0.05, number needed to treat: 12) without increasing the rate of major bleeding when prophylactically applied. Our goal was to identify predictive factors for sVTE in pts with APC undergoing first-line chemotherapy. Methods: We analyzed the 152 (out of 312) pts randomized in the observation group.SVTE incidence was 9.9%. To identify foremost risk factors we used clinical parameters like performance status, stage, grading, primary or recurrent, gender, age, body mass index, erythropoietin stimulating agents (darbepoetin), as well as baseline laboraty parameters such as creatinine, hemoglobin, WBC, platelets, INR, ptt, CEA, carboanhydrat 19-9, AST, ALT, AP and GGT. The multivariate logistic regression model with forward stepwise selection process was used for this estimation. With reference to a previously proposed scoring system (Khorana et al; Blood 2008) we evaluated the score as well. Results: No single parameter could be isolated demonstrating significant influence on the incidence of sVTE in pts with APC. We verified the Kohrana scoring model with our 152/312 pts. Applying the score to our pts we didn’t discriminate pts between the two high risks groups (Table). Conclusions: Predictive models may help to identify cancer pts at high risk for sVTE to consider preventive anticoagulation. Within a cancer entity at high risk for sVTE such as pts with APC we did not succeed in the identification of single predictive parameters.For pts with APC undergoing first line chemotherapy primary prevention with LMWH should therefore be considered for the whole group of pts for at least three months. [Table: see text]
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2012.30.15_suppl.4044
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2012
detail.hit.zdb_id:
2005181-5
detail.hit.zdb_id:
604914-X
Permalink